Literature DB >> 21859734

Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.

Vaishali Sanchorawala, Karen Quillen, J Mark Sloan, Nancy T Andrea, David C Seldin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21859734      PMCID： PMC3232278          DOI： 10.3324/haematol.2011.049858

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Vassiliki Poulaki; Yu-Tzu Tai; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Robert Schlossman; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

2.  Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

Authors:  David C Seldin; Jennifer J Anderson; Vaishali Sanchorawala; Karim Malek; Daniel G Wright; Karen Quillen; Kathleen T Finn; John L Berk; Laura M Dember; Rodney H Falk; Martha Skinner
Journal:  Blood       Date:  2004-05-20       Impact factor: 22.113

3.  Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

Authors:  Vaishali Sanchorawala; Martha Skinner; Karen Quillen; Kathleen T Finn; Gheorghe Doros; David C Seldin
Journal:  Blood       Date:  2007-08-02       Impact factor: 22.113

4.  Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Suzanne R Hayman; Shaji K Kumar; Nelson Leung; Dennis A Gastineau
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

5.  Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

Authors:  Murielle Roussel; Philippe Moreau; Anne Huynh; Jean-Yves Mary; Clotaire Danho; Denis Caillot; Cyrille Hulin; Christophe Fruchart; Gérald Marit; Brigitte Pégourié; Pascal Lenain; Carla Araujo; Brigitte Kolb; Edouard Randriamalala; Bruno Royer; Anne-Marie Stoppa; Mammoun Dib; Véronique Dorvaux; Laurent Garderet; Claire Mathiot; Hervé Avet-Loiseau; Jean-Luc Harousseau; Michel Attal
Journal:  Blood       Date:  2009-11-02       Impact factor: 22.113

6.  A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.

Authors:  Sagar Lonial; Jonathan Kaufman; Mourad Tighiouart; Ajay Nooka; Amelia A Langston; Leonard T Heffner; Claire Torre; Stephanie McMillan; Heather Renfroe; R Donald Harvey; Mary J Lechowicz; H Jean Khoury; Christopher R Flowers; Edmund K Waller
Journal:  Clin Cancer Res       Date:  2010-08-25       Impact factor: 12.531

7.  NF-kappa B as a therapeutic target in multiple myeloma.

Authors:  Teru Hideshima; Dharminder Chauhan; Paul Richardson; Constantine Mitsiades; Nicholas Mitsiades; Toshiaki Hayashi; Nikhil Munshi; Lenny Dang; Alfredo Castro; Vito Palombella; Julian Adams; Kenneth C Anderson
Journal:  J Biol Chem       Date:  2002-02-28       Impact factor: 5.157

8.  High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Authors:  Martha Skinner; Vaishali Sanchorawala; David C Seldin; Laura M Dember; Rodney H Falk; John L Berk; Jennifer J Anderson; Carl O'Hara; Kathleen T Finn; Caryn A Libbey; Janice Wiesman; Karen Quillen; Niall Swan; Daniel G Wright
Journal:  Ann Intern Med       Date:  2004-01-20       Impact factor: 25.391

9.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Philip R Greipp; Thomas E Witzig; John A Lust; S Vincent Rajkumar; Rafael Fonseca; Steven R Zeldenrust; Christopher G A McGregor; Allan S Jaffe
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

10.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245
View more
  6 in total

1.  Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.

Authors:  Vaishali Sanchorawala
Journal:  Am J Blood Res       Date:  2012-01-01

Review 2.  Role of stem cell transplant and maintenance therapy in plasma cell disorders.

Authors:  Philip L McCarthy; Sarah A Holstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

3.  A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.

Authors:  C P Venner; J D Gillmore; S Sachchithanantham; S Mahmood; T Lane; D Foard; L Rannigan; S D J Gibbs; J H Pinney; C J Whelan; H J Lachmann; P N Hawkins; A D Wechalekar
Journal:  Leukemia       Date:  2014-07-16       Impact factor: 11.528

4.  Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.

Authors:  S Parmar; P Kongtim; R Champlin; Y Dinh; Y Elgharably; M Wang; Q Bashir; J J Shah; N Shah; U Popat; S A Giralt; R Z Orlowski; M H Qazilbash
Journal:  Bone Marrow Transplant       Date:  2014-06-02       Impact factor: 5.483

Review 5.  Update on treatment of light chain amyloidosis.

Authors:  Shameem Mahmood; Giovanni Palladini; Vaishali Sanchorawala; Ashutosh Wechalekar
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

6.  Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.

Authors:  Xianghua Huang; Qingwen Wang; Wencui Chen; Caihong Zeng; Zhaohong Chen; Dehua Gong; Haitao Zhang; Zhihong Liu
Journal:  BMC Med       Date:  2014-01-06       Impact factor: 8.775
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.